TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

ADMA BioCenters Receives FDA Approval for Its Ninth Plasma Collection Center in Dallas, Georgia

Thursday, July 20, 2023

ADMA Biologics, Inc. (NASDAQ: ADMA) recently obtained FDA approval for its ninth ADMA BioCenters plasma collection facility located in Dallas, GA. The facility began operating and collecting source plasma in the third quarter of 2022. This FDA approval allows the facility to collect and distribute human source plasma for further manufacturing in the United States.

The expansion of ADMA's plasma collection network aligns with the company's mission of achieving plasma supply self-sufficiency, continuous revenue growth, and improved profitability. Adam Grossman, the President and CEO of ADMA, expressed gratitude to the FDA for their prompt review and approval, acknowledging the hard work and commitment of the BioCenters team.

Brian Lenz, the Executive Vice President, Chief Financial Officer, and General Manager of ADMA BioCenters, stated that with nine FDA-licensed plasma collection centers, they are on track to achieve their goal of having ten FDA-approved plasma collection centers for normal source plasma and hyperimmune plasma by the end of 2023.

The newly established plasma collection center in Dallas, GA is equipped with advanced technology, offering automated registration, high-tech collection equipment for a faster donation process, and amenities such as free Wi-Fi and individual flat-screen TVs with cable at each donor station. The center employs 50 highly trained healthcare workers, prioritizing donor comfort and safety. It has also received approval to utilize the state-of-the-art Haemonetics NexSys Persona® plasma collection system.

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit